

Caterina Scuderi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5895887/publications.pdf>

Version: 2024-02-01

59
papers

3,077
citations

172207

29
h-index

161609

54
g-index

59
all docs

59
docs citations

59
times ranked

3955
citing authors

#	ARTICLE	IF	CITATIONS
1	How useful are biomarkers for the diagnosis of Alzheimer's disease and especially for its therapy?. <i>Neural Regeneration Research</i> , 2022, 17, 2205.	1.6	6
2	Acute Ketamine Facilitates Fear Memory Extinction in a Rat Model of PTSD Along With Restoring Glutamatergic Alterations and Dendritic Atrophy in the Prefrontal Cortex. <i>Frontiers in Pharmacology</i> , 2022, 13, 759626.	1.6	17
3	Effects of Ultramicrosized Palmitoylethanolamide on Mitochondrial Bioenergetics, Cerebral Metabolism, and Glutamatergic Transmission: An Integrated Approach in a Triple Transgenic Mouse Model of Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, .	1.7	4
4	Co-Ultramicrosized Palmitoylethanolamide/Luteolin Restores Oligodendrocyte Homeostasis via Peroxisome Proliferator-Activated Receptor- α in an In Vitro Model of Alzheimer's Disease. <i>Biomedicines</i> , 2022, 10, 1236.	1.4	10
5	Sorafenib Chemosensitization by Caryophyllane Sesquiterpenes in Liver, Biliary, and Pancreatic Cancer Cells: The Role of STAT3/ABC Transporter Axis. <i>Pharmaceutics</i> , 2022, 14, 1264.	2.0	7
6	Alternative Targets to Fight Alzheimer's Disease: Focus on Astrocytes. <i>Biomolecules</i> , 2021, 11, 600.	1.8	16
7	Post-COVID-19 neuropsychiatric syndrome: Is maladaptive glial recovery to blame?. <i>Acta Physiologica</i> , 2021, 233, e13717.	1.8	7
8	Successful and Unsuccessful Brain Aging in Pets: Pathophysiological Mechanisms behind Clinical Signs and Potential Benefits from Palmitoylethanolamide Nutritional Intervention. <i>Animals</i> , 2021, 11, 2584.	1.0	5
9	Targeting the Oxytocinergic System: A Possible Pharmacological Strategy for the Treatment of Inflammation Occurring in Different Chronic Diseases. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10250.	1.8	13
10	Systemic Inflammation and Astrocyte Reactivity in the Neuropsychiatric Sequelae of COVID-19: Focus on Autism Spectrum Disorders. <i>Frontiers in Cellular Neuroscience</i> , 2021, 15, 748136.	1.8	7
11	Astrocytes: The Housekeepers and Guardians of the CNS. <i>Advances in Neurobiology</i> , 2021, 26, 21-53.	1.3	19
12	Principles of Astroglipathology. <i>Advances in Neurobiology</i> , 2021, 26, 55-73.	1.3	8
13	Neuroglia in Psychiatric Disorders. <i>Advances in Neurobiology</i> , 2021, 26, 3-19.	1.3	9
14	Astroglial Serotonin Receptors as the Central Target of Classic Antidepressants. <i>Advances in Neurobiology</i> , 2021, 26, 317-347.	1.3	7
15	The role of neuroglia in autism spectrum disorders. <i>Progress in Molecular Biology and Translational Science</i> , 2020, 173, 301-330.	0.9	18
16	Oleylethanolamide decreases frustration stress-induced binge-like eating in female rats: a novel potential treatment for binge-eating disorder. <i>Neuropsychopharmacology</i> , 2020, 45, 1931-1941.	2.8	36
17	Looking for a Treatment for the Early Stage of Alzheimer's Disease: Preclinical Evidence with Co-Ultramicrosized Palmitoylethanolamide and Luteolin. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3802.	1.8	24
18	Altered Waste Disposal System in Aging and Alzheimer's Disease: Focus on Astrocytic Aquaporin-4. <i>Frontiers in Pharmacology</i> , 2020, 10, 1656.	1.6	50

#	ARTICLE	IF	CITATIONS
19	Neuroinflammation in Alzheimer's Disease: Friend or Foe?. FASEB Journal, 2020, 34, 1-1.	0.2	9
20	The prokineticin receptor antagonist PC1 rescues memory impairment induced by β^2 amyloid administration through the modulation of prokineticin system. Neuropharmacology, 2019, 158, 107739.	2.0	18
21	Astrocyte Function Is Affected by Aging and Not Alzheimer's Disease: A Preliminary Investigation in Hippocampi of 3xTg-AD Mice. Frontiers in Pharmacology, 2019, 10, 644.	1.6	32
22	Early intrathecal infusion of everolimus restores cognitive function and mood in a murine model of Alzheimer's disease. Experimental Neurology, 2019, 311, 88-105.	2.0	41
23	Altered Brain Cholesterol/Isoprenoid Metabolism in a Rat Model of Autism Spectrum Disorders. Neuroscience, 2018, 372, 27-37.	1.1	48
24	An Animal Model of Alzheimer Disease Based on the Intrahippocampal Injection of Amyloid β^2 -Peptide (1 β 42). Methods in Molecular Biology, 2018, 1727, 343-352.	0.4	37
25	Preparation of Rat Hippocampal Organotypic Cultures and Application to Study Amyloid β^2 -Peptide Toxicity. Methods in Molecular Biology, 2018, 1727, 333-341.	0.4	0
26	Neuroglia in the autistic brain: evidence from a preclinical model. Molecular Autism, 2018, 9, 66.	2.6	63
27	Editorial: Neuroglia Molecular Mechanisms in Psychiatric Disorders. Frontiers in Molecular Neuroscience, 2018, 11, 407.	1.4	5
28	Palmitoylethanolamide Dampens Reactive Astrogliosis and Improves Neuronal Trophic Support in a Triple Transgenic Model of Alzheimer's Disease: <i>In Vitro</i> and <i>In Vivo</i> Evidence. Oxidative Medicine and Cellular Longevity, 2018, 2018, 1-14.	1.9	48
29	Ultramicronized palmitoylethanolamide rescues learning and memory impairments in a triple transgenic mouse model of Alzheimer's disease by exerting anti-inflammatory and neuroprotective effects. Translational Psychiatry, 2018, 8, 32.	2.4	64
30	Astrocyte: An Innovative Approach for Alzheimer's Disease Therapy. Current Pharmaceutical Design, 2018, 23, 4979-4989.	0.9	17
31	Astrocyte-neuron interplay in Alzheimer's disease: evidence from an innovative and promising pharmacological manipulation in a triple transgenic model of the disease. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO1-1-65.	0.0	0
32	Targeting neuroinflammation in Alzheimer's disease. Journal of Inflammation Research, 2016, Volume 9, 199-208.	1.6	198
33	How could retinoids fit into Alzheimer's therapy?. Drugs of the Future, 2016, 41, 0015.	0.0	3
34	S100B-p53 disengagement by pentamidine promotes apoptosis and inhibits cellular migration via aquaporin-4 and metalloproteinase-2 inhibition in C6 glioma cells. Oncology Letters, 2015, 9, 2864-2870.	0.8	28
35	Does neuroinflammation turn on the flame in Alzheimer's disease? Focus on astrocytes. Frontiers in Neuroscience, 2015, 9, 259.	1.4	72
36	Palmitoylethanolamide Regulates Production of Pro-Angiogenic Mediators in a Model of β^2 Amyloid-Induced Astrogliosis & In Vitro. CNS and Neurological Disorders - Drug Targets, 2015, 14, 828-837.	0.8	25

#	ARTICLE	IF	CITATIONS
37	Palmitoylethanolamide controls reactive gliosis and exerts neuroprotective functions in a rat model of Alzheimer's disease. <i>Cell Death and Disease</i> , 2014, 5, e1419-e1419.	2.7	79
38	Sirtuin modulators control reactive gliosis in an in vitro model of Alzheimer's disease. <i>Frontiers in Pharmacology</i> , 2014, 5, 89.	1.6	56
39	Cannabidiol Promotes Amyloid Precursor Protein Ubiquitination and Reduction of Beta Amyloid Expression in SHSY5Y APP+ Cells Through PPAR γ Involvement. <i>Phytotherapy Research</i> , 2014, 28, 1007-1013.	2.8	124
40	Cannabidiol in Inflammatory Bowel Diseases: A Brief Overview. <i>Phytotherapy Research</i> , 2013, 27, 633-636.	2.8	81
41	Role of astrocytes in major neurological disorders: The evidence and implications. <i>IUBMB Life</i> , 2013, 65, 957-961.	1.5	39
42	Neuroglial Roots of Neurodegenerative Diseases: Therapeutic Potential of Palmitoylethanolamide in Models of Alzheimer's Disease. <i>CNS and Neurological Disorders - Drug Targets</i> , 2013, 12, 62-69.	0.8	45
43	Are Retinoids a Promise for Alzheimer's Disease Management?. <i>Current Medicinal Chemistry</i> , 2012, 19, 6119-6125.	1.2	6
44	The antiprotozoal drug pentamidine ameliorates experimentally induced acute colitis in mice. <i>Journal of Neuroinflammation</i> , 2012, 9, 277.	3.1	29
45	Palmitoylethanolamide exerts neuroprotective effects in mixed neuroglial cultures and organotypic hippocampal slices via peroxisome proliferator-activated receptor- γ . <i>Journal of Neuroinflammation</i> , 2012, 9, 49.	3.1	97
46	Cannabidiol Reduces Intestinal Inflammation through the Control of Neuroimmune Axis. <i>PLoS ONE</i> , 2011, 6, e28159.	1.1	134
47	Cannabidiol Reduces $\text{A}\beta$ -Induced Neuroinflammation and Promotes Hippocampal Neurogenesis through PPAR γ Involvement. <i>PLoS ONE</i> , 2011, 6, e28668.	1.1	312
48	Palmitoylethanolamide counteracts reactive astrogliosis induced by $\text{A}\beta$ -amyloid peptide. <i>Journal of Cellular and Molecular Medicine</i> , 2011, 15, 2664-2674.	1.6	90
49	S100B and APP Promote a Gliocentric Shift and Impaired Neurogenesis in Down Syndrome Neural Progenitors. <i>PLoS ONE</i> , 2011, 6, e22126.	1.1	73
50	Are Anti-Angiogenic Drugs Useful in Neurodegenerative Disorders?. <i>CNS and Neurological Disorders - Drug Targets</i> , 2010, 9, 807-812.	0.8	6
51	Differential Cannabinoid Receptor Expression during Reactive Gliosis: a Possible Implication for a Nonpsychotropic Neuroprotection. <i>Scientific World Journal</i> , The, 2009, 9, 229-235.	0.8	9
52	Cannabidiol: A Promising Drug for Neurodegenerative Disorders?. <i>CNS Neuroscience and Therapeutics</i> , 2009, 15, 65-75.	1.9	179
53	Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders. <i>Phytotherapy Research</i> , 2009, 23, 597-602.	2.8	149
54	S100B induces tau protein hyperphosphorylation via Dickkopf-1 up-regulation and disrupts the Wnt pathway in human neural stem cells. <i>Journal of Cellular and Molecular Medicine</i> , 2008, 12, 914-927.	1.6	81

#	ARTICLE	IF	CITATIONS
55	Genomic and functional profiling of human Down syndrome neural progenitors implicates S100B and aquaporin 4 in cell injury. <i>Human Molecular Genetics</i> , 2008, 17, 440-457.	1.4	101
56	Opposing Control of Cannabinoid Receptor Stimulation on Amyloid- β^2 -Induced Reactive Gliosis: In Vitro and in Vivo Evidence. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 322, 1144-1152.	1.3	72
57	Cannabidiol in vivo blunts β^2 -amyloid induced neuroinflammation by suppressing IL-1 β^2 and iNOS expression. <i>British Journal of Pharmacology</i> , 2007, 151, 1272-1279.	2.7	235
58	Cannabinoid CB1 receptor stimulation affords neuroprotection in MPTP-induced neurotoxicity by attenuating S100B up-regulation in vitro. <i>Journal of Molecular Medicine</i> , 2007, 85, 1379-1392.	1.7	41
59	CB1 receptor selective activation inhibits β^2 -amyloid-induced iNOS protein expression in C6 cells and subsequently blunts tau protein hyperphosphorylation in co-cultured neurons. <i>Neuroscience Letters</i> , 2006, 404, 342-346.	1.0	68